From Financial Modeling Prep: 2025-05-14 07:00:00

Bright Minds Biosciences Inc. (NASDAQ:DRUG) is focused on developing serotonin-based medicines for severe diseases like epilepsy and pain. Collaborating with institutions like NIH, the company’s stock has a stable average target of $80, showing consistent analyst expectations. With a high-risk, high-reward profile, Bright Minds is advancing treatments for epilepsy, including drug-resistant cases.

Analyst Patrick Trucchio sets a price target of $85 for Bright Minds Biosciences, indicating a potential upside of over 150%. Their innovative drug, BMB-101, targets drug-resistant epilepsy, tapping into a multibillion-dollar market. With a phase 2 trial for Absence Epilepsy and DEE underway, the company’s $35 million private placement ensures continued research and development beyond 2026.



Read more at Financial Modeling Prep:: Bright Minds Biosciences Inc. (NASDAQ: DRUG) Targe…